Abstract
Objective
Compare the efficacy of new agents netarsudil 0.02% (NET) and latanoprostene bunod
0.024% (LB) ophthalmic solutions as adjuncts to traditional 4-class maximum medical
therapy (MMT) in primary open angle glaucoma (POAG).
Design
Single-centre retrospective cohort study using records from a university glaucoma
clinic from 2017 to 2021 with follow-up at 30–90 days.
Participants
Patients with POAG already taking 4-class MMT who either added NET (n = 24) or exchanged
a currently prescribed prostaglandin analogue (PGA) for LB (n = 11) with no prior
surgery except for selective laser trabeculoplasty or cataract extraction >1 year
prior.
Methods
Either addition of NET or exchange of PGA for LB and otherwise continuing MMT. Outcome
measures were absolute intraocular pressure reduction (IOPR) in mm Hg, percent IOPR,
and proportion of patients achieving >10% IOPR.
Results
Data from 35 eyes in 35 patients were analyzed. Intraocular pressure reduction after
adding NET was significantly greater than after exchanging a PGA for LB. Percent IOPR
by NET also was significantly greater than after exchanging PGA for LB. The proportion
of patients reaching therapeutic threshold after the addition of NET was significantly
greater than after exchange of PGA for LB.
Conclusions
In patients with POAG on MMT, addition of NET was associated with significantly greater
magnitude of IOPR and a significantly greater proportion of patients reaching the
>10% IOPR threshold compared with exchange of PGA for LB.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of OphthalmologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Maximal medical therapy for glaucoma.Arch Ophthalmol. 1997; 115: 1579-1580
- Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date.Clin Ophthalmol. 2018; 12: 1939-1944
- Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.Expert Opin Pharmacother. 2017; 18: 433-444
- Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings.J Glaucoma. 2018; 27: 7-15
- Netarsudil for the treatment of open-angle glaucoma and ocular hypertension: a literature review.Ann Pharmacother. 2020; 1060028020971215
- A clinician's guide to the assessment and management of nonadherence in glaucoma.Ophthalmology. 2009; 116: S43-S47
- Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma.Eur J Ophthalmol. 2021; 1120672121998913
- A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting.Curr Med Res Opin. 2021; 37: 1011-1020
- Effectiveness of netarsudil as an additional therapy for glaucoma in patients already on maximally tolerated medical therapy.Clin Ophthalmol. 2021; 15: 4367-4372
- Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome.Eye (Lond). 2017; 31: 771-775
- Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study.Ophthalmology. 2016; 123: 965-973
- A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.Br J Ophthalmol. 2015; 99: 738-745
- Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study.Am J Ophthalmol. 2016; 168: 250-259
- Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).Am J Ophthalmol. 2018; 186: 116-127
- Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).Am J Ophthalmol. 2019; 200: 130-137
- Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study.Am J Ophthalmol. 2019; 204: 97-104
- A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol.Eur J Ophthalmol. 2000; 10: 95-104
Article Info
Publication History
Published online: April 11, 2022
Accepted:
March 13,
2022
Received in revised form:
November 12,
2021
Received:
June 7,
2021
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2022 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.
